Viewing Study NCT04055792


Ignite Creation Date: 2025-12-24 @ 3:17 PM
Ignite Modification Date: 2026-01-02 @ 4:22 AM
Study NCT ID: NCT04055792
Status: COMPLETED
Last Update Posted: 2023-06-28
First Post: 2019-08-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Sponsor: Henan Cancer Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module